|
Name |
Cristatumin C
|
| Molecular Formula | C33H38N6O | |
| IUPAC Name* |
3-methylidene-9-(4-methyl-3,6-dimethylidene-2,5,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-10,12,14-trien-9-yl)-4-propan-2-yl-2,5,16-triazatetracyclo[7.7.0.02,7.010,15]hexadeca-10,12,14-trien-6-one
|
|
| SMILES |
C=C1NC(C)C(=C)N2C1CC1(C34CC5C(=O)NC(C(C)C)C(=C)N5C3Nc3ccccc34)c3ccccc3NC21
|
|
| InChI |
InChI=1S/C33H38N6O/c1-17(2)28-21(6)39-27(29(40)37-28)16-33(23-12-8-10-14-25(23)36-31(33)39)32-15-26-19(4)34-18(3)20(5)38(26)30(32)35-24-13-9-7-11-22(24)32/h7-14,17-18,26-28,30-31,34-36H,4-6,15-16H2,1-3H3,(H,37,40)/t18-,26-,27-,28-,30+,31+,32?,33-/m1/s1
|
|
| InChIKey |
KYGBZFMUPGPMMB-HTOCGNBQSA-N
|
|
| Synonyms |
NA
|
|
| CAS | NA | |
| PubChem CID | NA | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 534.71 | ALogp: | 4.2 |
| HBD: | 4 | HBA: | 6 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 71.7 | Aromatic Rings: | 8 |
| Heavy Atoms: | 40 | QED Weighted: | 0.445 |
| Caco-2 Permeability: | -5.343 | MDCK Permeability: | 0.00020260 |
| Pgp-inhibitor: | 0.888 | Pgp-substrate: | 0.035 |
| Human Intestinal Absorption (HIA): | 0.562 | 20% Bioavailability (F20%): | 0.004 |
| 30% Bioavailability (F30%): | 0.975 |
| Blood-Brain-Barrier Penetration (BBB): | 0.021 | Plasma Protein Binding (PPB): | 95.63% |
| Volume Distribution (VD): | 1.628 | Fu: | 3.44% |
| CYP1A2-inhibitor: | 0.013 | CYP1A2-substrate: | 0.055 |
| CYP2C19-inhibitor: | 0.952 | CYP2C19-substrate: | 0.412 |
| CYP2C9-inhibitor: | 0.943 | CYP2C9-substrate: | 0.08 |
| CYP2D6-inhibitor: | 0.192 | CYP2D6-substrate: | 0.243 |
| CYP3A4-inhibitor: | 0.965 | CYP3A4-substrate: | 0.921 |
| Clearance (CL): | 5.109 | Half-life (T1/2): | 0.023 |
| hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.382 |
| Drug-inuced Liver Injury (DILI): | 0.755 | AMES Toxicity: | 0.047 |
| Rat Oral Acute Toxicity: | 1 | Maximum Recommended Daily Dose: | 0.929 |
| Skin Sensitization: | 0.34 | Carcinogencity: | 0.445 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
| Respiratory Toxicity: | 0.975 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003424 | ![]() |
0.674 | D0K4CQ | ![]() |
0.245 | ||
| ENC002594 | ![]() |
0.381 | D0V9WF | ![]() |
0.238 | ||
| ENC004848 | ![]() |
0.367 | D03KQF | ![]() |
0.232 | ||
| ENC001500 | ![]() |
0.362 | D0E0RY | ![]() |
0.232 | ||
| ENC003381 | ![]() |
0.330 | D09NNH | ![]() |
0.230 | ||
| ENC003490 | ![]() |
0.328 | D0J6WW | ![]() |
0.229 | ||
| ENC004849 | ![]() |
0.324 | D0J7XL | ![]() |
0.224 | ||
| ENC003176 | ![]() |
0.324 | D00HZV | ![]() |
0.222 | ||
| ENC003601 | ![]() |
0.321 | D0R6RO | ![]() |
0.220 | ||
| ENC003382 | ![]() |
0.319 | D01TSI | ![]() |
0.216 | ||